SAN DIEGO, May 14, 2019 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, today announced the Company
continues its commitment to the Society of Lateral Access Surgery
(SOLAS) as a Global Partner, the leading sponsorship level in the
partnership program, at the 12th annual SOLAS meeting
being held May 16-18, 2019
in Miami, Florida. NuVasive
will also participate in exhibit and workshop programs, featuring
its comprehensive approach to lateral single-position surgery with
the X360™ system integrated with Surgical Intelligence™.
During the meeting, NuVasive will host a lunch
symposia, X360 powered by Surgical Intelligence, presented
by Brett Braly, MD, and Brian Kwon, MD, on May
17, 2019 from 12:45 to 2:15 p.m.
ET. This symposia will discuss the X360 approach, clinical
utilization of NuVasive's Modulus® and
Cohere® XLIF® interbody implants and clinical
case reviews.
In addition, Dr. Braly will present his paper, "The effect of
radiation reduction technology on fluoroscope radiation emission
during lumbar interbody fusion for degenerative spinal conditions,"
during the scientific sessions highlighting new technologies and
techniques on May 17. These
preliminary, comparative results suggest the low-dose fluoroscopic
images NuVasive's LessRay image enhancement platform provides are
of similar diagnostic capability needed to successfully perform
lateral-position interbody fusion and posterior fixation, with
nearly 60% reduction in radiation emission.
"NuVasive's ongoing partnership and support of SOLAS is
representative of our deep commitment to advancing the latest
knowledge and technological advancements within lateral access
surgery," said Matt Link, president of NuVasive. "As the only
SOLAS Global Partner, NuVasive continues to lead lateral spine
surgery with enabling technologies, surgeon education and clinical
research to help surgeons deliver more reproducible clinical
outcomes in spine surgery."
SOLAS and NuVasive align in their missions to advance
minimally invasive surgery (MIS) in spine. MIS is the fastest
growing sub-market in spine, driven by innovation from NuVasive
that continues to push the boundaries of lateral
surgery. Sixteen years ago, NuVasive revolutionized spine
surgery with XLIF, the only lateral approach spine procedure
supported by extensive clinical evidence in more than 400
peer-reviewed publications. Now, with the recent introduction of
the X360 system, NuVasive has delivered the most comprehensive
approach to lateral single-position surgery, leveraging advanced
techniques and technologies to deliver best-in-class care, while
enhancing operating room workflow and efficiency.
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
more than $1 billion in revenues,
NuVasive has approximately 2,600 employees and operates in more
than 50 countries serving surgeons, hospitals and patients. For
more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA® platform), the Company's ability to effectually
manage inventory as it continues to release new products, its
ability to recruit and retain management and key personnel, and the
other risks and uncertainties described in NuVasive's news releases
and periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nuvasive-to-participate-as-global-partner-at-12th-annual-society-of-lateral-access-surgery-meeting-300849394.html
SOURCE NuVasive, Inc.